Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04619381 Withdrawn - Clinical trials for Coronary Artery Disease

Causes of Health Disparities in African Americans With Coronary Artery Disease on Clopidogrel

Start date: March 19, 2021
Phase:
Study type: Observational

African Americans with coronary artery disease who have been prescribed clopidogrel (also known as Plavix), an antiplatelet drug will be enrolled. The purpose of this study is to help identify why African Americans are at an increased risk of having a major heart attack or stroke after a common procedure to open up blocked arteries with stents. The knowledge to be gained from this study includes: 1. A better understanding of the metabolism of the antiplatelet drug, clopidogrel, and abnormal platelet function in African Americans; this understanding may provide a basis for potential future therapy 2. A better understanding of challenges to taking clopidogrel as prescribed by a doctor and opinions about a genetic test related to this medicine.

NCT ID: NCT04379947 Withdrawn - Clinical trials for Coronary Artery Disease

Preoperative Use of Fractional Flow Reserve in CABG Use and Effectiveness of FFR-based CABG in Real-life Practice

Start date: May 2020
Phase:
Study type: Observational

The use of fractional flow reserve (FFR) to guide coronary artery bypass graft (CABG) is controversial and not ubiquitously adopted across the units. There is no definitive evidence that the use of FFR improves early clinical outcomes after CABG, with the exception of a simplification of the procedure. FFR use may help in defining the indication to the use arterial grafts, but there is no evidence that preoperative FFR lead to any benefits in terms of patency when venous grafts are used. On these grounds a large multicentric all-comers observational study is planned. The aim is to achieve a real-life picture of the FFR practice in CABG across several European and non-European units. This study will inform on the effective use rate of FFR in the CABG practice and its clinical effectiveness when compared to standard angiography-based CABG.

NCT ID: NCT04361552 Withdrawn - Clinical trials for Coronary Artery Disease

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Start date: April 7, 2020
Phase: Phase 3
Study type: Interventional

This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

NCT ID: NCT04069234 Withdrawn - Diabetes Mellitus Clinical Trials

Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

AUGEAS
Start date: September 15, 2019
Phase: Phase 3
Study type: Interventional

This study is designed to test the hypothesis that ticagrelor is superior to clopidogrel, in improving coronary microvascular function, as measured by coronary flow reserve (CFR) in patients with T2DM at high risk of cardiovascular (CV) events undergoing elective PCI.

NCT ID: NCT04059536 Withdrawn - Clinical trials for Coronary Artery Disease

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Start date: October 31, 2019
Phase:
Study type: Observational

The purpose of this registry study is to gather real world standard of care (SOC) data on the safety and performance on the Roxwood Medical catheter devices in the treatment of stenotic lesions and CTO.

NCT ID: NCT03953040 Withdrawn - Clinical trials for Coronary Artery Disease

Role of Intracoronary Imaging in Plaque Identification

Start date: April 1, 2019
Phase:
Study type: Observational

NSTE-ACS patients are more likely to exhibit high-risk plaque characteristics in non-culprit lesions. Both IVUS and OCT imaging techniques interact in a complementary manner to provide morphological characterization of the atherosclerotic coronary plaques and help identification of high-risk vulnerable plaques. Using morphological parameters obtained from OCT and IVUS, a new plaque vulnerability score will be established for more precise definition of the most vulnerable plaques that carry the greatest risk of rupture and subsequent detrimental clinical outcomes in the future. Such score might help in targeting these plaques with certain therapeutic interventions aiming to their stabilization.

NCT ID: NCT03851276 Withdrawn - Clinical trials for Multivessel Coronary Artery Disease

A Multicentre, Pilot Study to Evaluate the Safety and the Feasibility of Planning and Execution of Surgical Revascularization in Patients With Complex Coronary Artery Disease, Based Solely on MSCT Imaging Utilizing GE Healthcare Revolution CT and HeartFlow FFRCT.

CABGRevolution
Start date: June 28, 2019
Phase: Phase 4
Study type: Interventional

The CABG-REVOLUTION study is an investigator-initiated single-arm, multicentre, prospective study for patients with 3-vessel disease (with or without left-main involvement) referred to CABG treatment. Surgical revascularization strategy and treatment planning will be solely based on MSCT (with FFRCT) without knowledge of the anatomy defined by conventional cine-angiography.

NCT ID: NCT03851263 Withdrawn - Clinical trials for Coronary Artery Disease

Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion

MARKOV
Start date: August 30, 2019
Phase: Phase 4
Study type: Interventional

The MARKOV study is an investigator-sponsored single arm, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) after 18 and 36 months of treatment in patients with coronary atherosclerosis.

NCT ID: NCT03743090 Withdrawn - Clinical trials for Coronary Artery Disease

Influence of Extracorporeal Circulation on the Development of OSA (Obstructive Sleep Apnea)

Start date: August 1, 2019
Phase:
Study type: Observational

- 1. Coronary artery bypass grafting (CABG) could be performed with or without extracorporeal circulation (ECC). - 2. OSA (Obstructive Sleep Apnea) could be influenced by in intravenous perfusion. - 3. ECC could influence the amount of intravenous perfusion administered to the patient. The aim of this study was to examine the influence of ECC on the development of OSA.

NCT ID: NCT03446599 Withdrawn - Clinical trials for Coronary Artery Disease

Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery

Start date: November 2019
Phase: Phase 2
Study type: Interventional

This is a pilot study to determine the hemodynamic effects when hydroxocobalamin vs methylene blue is administered during cardiopulmonary bypass in patients at risk of vasoplegia by measuring mean arterial pressure (MAP), systemic vascular resistance (SVR) and vasopressor requirement.